INmune Bio, Inc. announces two presentations at the upcoming 18th Clinical Trials on Alzheimer's Disease conference (CTAD) in San Diego, CA.
The presentations focus on XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation, and the Validation of the Early Mild Alzheimer's Cognitive Composite (EMACC) through associations with blood-based biomarkers of Alzheimer's Disease.
Presenting authors are Kim A. Staats, PhD from INmune Bio, and Sarah Barnum, PhD from Cognition Metrics.
Product Platforms
INmune Bio's product platforms include DN-TNF, CORDStrom™, and INKmune®.
Clinical Trials
The company's programs are in clinical trials addressing diseases like Alzheimer's and cancer.
Forward Looking Statements
There are risks and uncertainties related to the development and commercialization of product candidates.
- INmune Bio focuses on developing treatments targeting immunology and inflammation.
- The company's programs aim to address innate immune dysfunction and eliminate minimal residual disease in cancer patients.
INmune Bio's participation in the CTAD conference highlights its commitment to advancing treatments for Alzheimer's disease and cancer patients.